IBM Micromedex NeoFax
8.4 7
v3.4.0 por Mobile Micromedex
Sobre IBM Neofax
IBM Micromedex NeoFax app is available free to online subscribers of IBM Micromedex NeoFax.
IBM Micromedex NeoFax is a reliable resource for on-the-go access to evidence-based drug information to efficiently and safely manage drug therapy for neonatal patients. It allows clinicians to make accurate and more informed treatment decisions at the point of care, while minimizing errors in this vulnerable patient population. This neonatal-specific app has clinical value for doctors, nurses, and pharmacists. An internet connection is not required, allowing you to make decisions with confidence at anytime, from anywhere.
IBM Micromedex is a trusted source for neonatal drug dosing, based on the strict editorial policies and practices that have guided Micromedex for more than 30 years. Evidence-based, fully referenced neonatal-specific drug information enables clinicians to make informed treatment decisions. The drug monographs cover information including: dose, administration, uses, contraindications/precautions, adverse effects, monitoring, pharmacology, special considerations/preparation, solution- and drug-drug compatibility/incompatibility information, and references. This mobile app also includes a comprehensive enteral formulas component providing nutritional information for approximately 60 different neonatal and infant formulas, and human milk fortifiers.
IBM Micromedex NeoFax drug information is intended for full-term babies up to 28 days of age (PNA) and preterm babies up to 44 weeks postmenstrual age (GA + PNA).
Do you work at a facility that subscribes to IBM Micromedex NeoFax? Check with your Chief of Pediatrics, Director of Pediatrics, Director of the NICU, Directory of Pharmacy, Chief Medical Officer, Chief Nursing Officer, Medical Librarian, or anyone else at your facility responsible for clinical reference information.
If you work at a facility that subscribes to IBM Micromedex NeoFax, FREE access to these apps requires a password. To obtain the IBM Micromedex NeoFax password contact support at https://www.ibm.com/support/home/pages/support-guide/?product=4592217
Existing paid customers will continue to have access to the content going forward.
IBM Micromedex NeoFax is a reliable resource for on-the-go access to evidence-based drug information to efficiently and safely manage drug therapy for neonatal patients. It allows clinicians to make accurate and more informed treatment decisions at the point of care, while minimizing errors in this vulnerable patient population. This neonatal-specific app has clinical value for doctors, nurses, and pharmacists. An internet connection is not required, allowing you to make decisions with confidence at anytime, from anywhere.
IBM Micromedex is a trusted source for neonatal drug dosing, based on the strict editorial policies and practices that have guided Micromedex for more than 30 years. Evidence-based, fully referenced neonatal-specific drug information enables clinicians to make informed treatment decisions. The drug monographs cover information including: dose, administration, uses, contraindications/precautions, adverse effects, monitoring, pharmacology, special considerations/preparation, solution- and drug-drug compatibility/incompatibility information, and references. This mobile app also includes a comprehensive enteral formulas component providing nutritional information for approximately 60 different neonatal and infant formulas, and human milk fortifiers.
IBM Micromedex NeoFax drug information is intended for full-term babies up to 28 days of age (PNA) and preterm babies up to 44 weeks postmenstrual age (GA + PNA).
Do you work at a facility that subscribes to IBM Micromedex NeoFax? Check with your Chief of Pediatrics, Director of Pediatrics, Director of the NICU, Directory of Pharmacy, Chief Medical Officer, Chief Nursing Officer, Medical Librarian, or anyone else at your facility responsible for clinical reference information.
If you work at a facility that subscribes to IBM Micromedex NeoFax, FREE access to these apps requires a password. To obtain the IBM Micromedex NeoFax password contact support at https://www.ibm.com/support/home/pages/support-guide/?product=4592217
Existing paid customers will continue to have access to the content going forward.
Actualización de IBM Neofax 3.4.0
• Updates in preparation for the sunsetting of the app. For more information, email our team with questions at: ProductSupport@Merative.com
Más información
Características de IBM Neofax
Versiones antiguas
Más
Requires Android: Android 4.4+
Architecture: arm64-v8a, armeabi-v7a, x86, x86_64
Screen DPI: 120-640dpi
SHA1: ec9c659a680f35eff2d1417ccc29c12b8c429f63
Size: 13.54 MB
What's New:
• Updates in preparation for the sunsetting of the app. For more information, email our team with questions at: ProductSupport@Merative.com
Requires Android: Android 4.4+
Architecture: arm64-v8a, armeabi-v7a, x86, x86_64
Screen DPI: 120-640dpi
SHA1: f5689d076b5d836af4afff0ac2793820f39840d5
Size: 13.54 MB
What's New:
• Bug fixes
Requires Android: Android 4.4+
Architecture: arm64-v8a, armeabi-v7a, x86, x86_64
Screen DPI: 120-640dpi
SHA1: 6437eb33c6929706b9cfbac7aaffeee5c4397534
Size: 13.54 MB
What's New:
• Bug fixes
Requires Android: Android 4.4+
Architecture: arm64-v8a, armeabi-v7a, x86, x86_64
Screen DPI: 120-640dpi
SHA1: 3854325c783b7957b2b8cc43979bc68d010d28cf
Size: 13.56 MB
What's New:
• Addition of a new support email address to reflect the new branding.
• Bug fixes
• Bug fixes
Más información
Nombre de paquete:
Categoría:
Fecha de actualización:
2022-10-30
Última versión:
3.4.0
Pedir actualización:
Requisitos:
Android 4.4+
Denunciar:
Descarga segura
APKFab.com y el enlace de descarga de esta aplicación son 100% seguros. Todos los enlaces de descarga de aplicaciones que aparecen en APKFab.com son de Google Play Store o enviados por los usuarios. Para la aplicación desde Google Play Store, APKFab.com no lo modificará de ninguna manera. Para la aplicación enviada por los usuarios, APKFab.com verificará la seguridad de la firma de APK antes de publicarla en nuestro sitio web.